Atrial fibrillation: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• GLP-1 5
• SGLT2 5
• NLRP3 0
• BTK 3
• AMPK 0
• PI3K 0
• GIP 3
• PPAR 0
• TTR 0
• AKT 0
• PCSK9 0
• STAT3 0
• BDNF 1
• COX-2 0
• ERK 0
• HMGB1 0
• HSP90 0
• IL-6 0
• METTL3 0
• NRF2 0
• PD-1 0
• PD-L1 0
• TP53 0
• VEGF 0
• ABL1 0
• ALK 0
• ANGPTL3 0
• APOE 0
• CD40 0
• CDK4/6 0
• CFTR 0
• EGFR 0
• FTO 0
• HER3 0
• HIF-1 0
• IGF1R 0
• RUNX1 0
• SIRT1 0
• STING 0
• STK11 0
• TLR4 0
• TNF 0
• TREM2 0
• YAP 0

24 of 3,815 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Integrative Modeling of Autonomic dysfunction and Cardiac arrhyThmogenesis (IMpACT)

  Politecnico di Milano· Milano, Italy· EU contribution €193,643· until Aug 2029· 3 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Molecular, cellular, and pharmacological characterization of a new modality of familial arrhythmia (Na-CPVT)

  Linkopings Universitet· Linkoping, Sweden· EU contribution €252,180· until Jan 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Holistic Efficient Arrhythmic Risk Twinning for Post-MI Stratification (HEART-TWIN)

  Universidad Pompeu Fabra· Barcelona, Spain· EU contribution €209,915· until Dec 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A computational framework for personalising atrial fibrillation treatment to minimise heart failure risk (AFHF-TAILOR)

  Eidgenoessische Technische Hochschule Zuerich· Zuerich, Switzerland· EU contribution €292,119· until Dec 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Advanced Tissue Engineering, Bioprinting, and 5D Optogenetics for Arrhythmia Investigation and Treatment (OptoPrintRhythm)

  Technion - Israel Institute of Technology· Haifa, Israel· EU contribution €3,375,000· until Dec 2031

5 of 43 running projects, newest first. Listed amounts together: €148.3m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Bariatric Surgery Evaluation and Assessment of Treatment Efficacy - Intervention Trial

  NCT06065124· University Medical Center Groningen· Updated 12 Nov 2026

  “slow patient inclusion”Registry text, quoted unchanged. Source

• Terminated

  Post Intensive Care Unit Atrial Fibrillation

  NCT05860894· Centre Hospitalier Universitaire de Besancon· Updated 22 Oct 2026

  “Insufficient recruitment”Registry text, quoted unchanged. Source

• Terminated

  Peripheral Nerve Stimulation Therapy for Atrial Fibrillation

  NCT05653583· Cala Health, Inc.· Updated 21 Oct 2026

  “The Sponsor and Principal Investigator have mutually agreed to initiate study closure due to prolonged recruitment challenges that have prevented the trial from meeting its enrollment milestones within the projected study timeline.”Registry text, quoted unchanged. Source

• Suspended

  A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination

  NCT06168942· Jaguar LAA, Inc.· Updated 19 Oct 2026

  “Potential unwrapping of the LAA post implant with clinically significant leaks.”Registry text, quoted unchanged. Source

• Terminated

  Clinical Implication of Atrial Fibrillation Detection Using Wearable Device in Patients With Cryptogenic Stroke

  NCT04624646· Ewha Womans University Mokdong Hospital· Updated 13 Oct 2026

  “Enrollment was closed early in July 2025 because of slow recruitment (338 of 600 planned participants; 324 were required for the superiority comparison). The 12-month follow-up period for all randomized participants ended in July 2026.”Registry text, quoted unchanged. Source

• Withdrawn

  Minocycline Plus Amiodarone Versus Amiodarone Alone for the Prevention of Atrial Fibrillation After Cardiac Surgery

  NCT01422148· Baystate Medical Center· Updated 30 Sept 2026

  “NOT ENOUGH PARTICIPANTS”Registry text, quoted unchanged. Source

• Suspended

  The CONFORM Pivotal Trial

  NCT05147792· Conformal Medical, Inc· Updated 25 Sept 2026

  “Enrollment has been temporarily suspended out of an abundance of caution and in close consultation with trial leadership and regulatory bodies to review overall study data thoroughly following a serious adverse event.”Registry text, quoted unchanged. Source

• Withdrawn

  Sweet spoT for cArdiac Rhythm monitorinG After sTrokE

  NCT05717504· Luciano A. Sposato· Updated 18 Sept 2026

  “Withdrawn before enrollment because new clinical evidence made the study question no longer relevant.”Registry text, quoted unchanged. Source

• Terminated

  Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control

  NCT02025465· CAMC Health System· Updated 10 Sept 2026

  “Low enrollment and PI retired.”Registry text, quoted unchanged. Source

• Terminated

  Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

  NCT02928497· Boston Scientific Corporation· Updated 25 Aug 2026

  “The enrollment was prematurely terminated on October 15, 2020, with 481 randomized patients. As discussed in the ASAP-TOO Update Meeting held on 16-September-2020 with FDA (Q150603-S001-A005), termination of enrollment was not due to safety concerns”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• SIMPLAAFY Clinical Trial

  NCT06521463· Boston Scientific Corporation· Source

• Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable

  NCT07430956· Regeneron Pharmaceuticals· Source

• Alert-HF: Early Detection and Intervention on Atrial Fibrillation in Heart Failure Patients

  NCT07816458· Medisch Spectrum Twente· Source

• Partial Cardiac Denervation for Preventing Atrial Fibrillation After CABG

  NCT07918781· China National Center for Cardiovascular Diseases· Source

• Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

  NCT07175428· Regeneron Pharmaceuticals· Source

• Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

  NCT07626411· Regeneron Pharmaceuticals· Source

• A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF

  NCT07429214· Biosense Webster, Inc.· Source

• Thrombolysis in Factor Xa-inhibitors Trial

  NCT06878066· Guri Hagberg· Source

• A Study of Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter With TRUPULSE™ Generator in Persistent Atrial Fibrillation

  NCT07845682· Biosense Webster, Inc.· Source

• A Study of Varipulse Catheter in Participants With Paroxysmal Atrial Fibrillation Under Optimized Sedation

  NCT07511166· Johnson & Johnson Medical (Shanghai) Ltd.· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 5
• Organoids 1
• Mendelian Randomization Analysis 75
• Gene Expression Profiling 31
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 16
• Metabolomics 14
• Mass Spectrometry 3
• Flow Cytometry 2
• Immunohistochemistry 2
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 67
• Machine Learning 88
• Deep Learning 35
• Cohort Studies 220
• Genome-Wide Association Study 62

• Combined immunohistochemical and proteomic description of neutrophil extracellular trap burden in acute ischemic stroke thrombi.

  J Thromb Haemost, Jan 2026

• Simvastatin attenuates the oxidative stress, endothelial thrombogenicity and the inducibility of atrial fibrillation in a rat model of ischemic heart failure.

  Int J Mol Sci, Aug 2014

See which targets of this disease your abstract mentions, and go to the people working on them.